NO20020605D0 - Anvendelse av CGRP-antagonister og CGRP- frigjöringsinhibitorer for bekjempelse av menopause-varmetokter - Google Patents

Anvendelse av CGRP-antagonister og CGRP- frigjöringsinhibitorer for bekjempelse av menopause-varmetokter

Info

Publication number
NO20020605D0
NO20020605D0 NO20020605A NO20020605A NO20020605D0 NO 20020605 D0 NO20020605 D0 NO 20020605D0 NO 20020605 A NO20020605 A NO 20020605A NO 20020605 A NO20020605 A NO 20020605A NO 20020605 D0 NO20020605 D0 NO 20020605D0
Authority
NO
Norway
Prior art keywords
cgrp
heatstroke
menopause
combating
release inhibitors
Prior art date
Application number
NO20020605A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020605L (no
Inventor
Henri Doods
Klaus Rudolf
Wolfgang Eberlein
Wolfhard Engel
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20020605L publication Critical patent/NO20020605L/no
Publication of NO20020605D0 publication Critical patent/NO20020605D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20020605A 1999-08-10 2002-02-07 Anvendelse av CGRP-antagonister og CGRP- frigjöringsinhibitorer for bekjempelse av menopause-varmetokter NO20020605D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937304A DE19937304C2 (de) 1999-08-10 1999-08-10 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
PCT/EP2000/007613 WO2001010425A2 (de) 1999-08-10 2000-08-05 Verwendung von cgrp-antagonisten und cgrp-release-hemmern zur bekämpfung menopausaler hitzewallungen

Publications (2)

Publication Number Publication Date
NO20020605L NO20020605L (no) 2002-02-07
NO20020605D0 true NO20020605D0 (no) 2002-02-07

Family

ID=7917551

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020605A NO20020605D0 (no) 1999-08-10 2002-02-07 Anvendelse av CGRP-antagonister og CGRP- frigjöringsinhibitorer for bekjempelse av menopause-varmetokter

Country Status (32)

Country Link
EP (1) EP1207884B1 (zh)
JP (1) JP2003506403A (zh)
KR (1) KR100713573B1 (zh)
CN (1) CN1166361C (zh)
AR (1) AR025078A1 (zh)
AT (1) ATE281168T1 (zh)
AU (1) AU777709B2 (zh)
BG (1) BG65366B1 (zh)
BR (1) BR0013009A (zh)
CA (1) CA2378428C (zh)
CZ (1) CZ300513B6 (zh)
DE (2) DE19937304C2 (zh)
EA (1) EA007531B1 (zh)
EE (1) EE04928B1 (zh)
ES (1) ES2231243T3 (zh)
HK (1) HK1046854B (zh)
HR (1) HRP20020117A2 (zh)
HU (1) HUP0202397A3 (zh)
IL (1) IL148057A (zh)
MX (1) MXPA02001373A (zh)
MY (1) MY129668A (zh)
NO (1) NO20020605D0 (zh)
NZ (1) NZ517367A (zh)
PL (1) PL198483B1 (zh)
PT (1) PT1207884E (zh)
SK (1) SK285587B6 (zh)
TR (1) TR200200359T2 (zh)
TW (1) TWI285550B (zh)
UA (1) UA73137C2 (zh)
WO (1) WO2001010425A2 (zh)
YU (1) YU8302A (zh)
ZA (1) ZA200200997B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
US7115609B2 (en) 2001-12-12 2006-10-03 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10227294A1 (de) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2005004869A1 (en) * 2003-07-07 2005-01-20 Boehringer Ingelheim International Gmbh Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
EP1646611A1 (en) * 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9610375A (pt) * 1995-09-07 1999-07-06 Oreal Extrato de células composição cosmética ou farmacêutica utilização de pelo menos um extrato de células e processo de tratamento cosmético
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
NZ334543A (en) * 1996-09-10 2000-06-23 Thomae Gmbh Dr K Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays
DE19911039A1 (de) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
PL198483B1 (pl) 2008-06-30
KR20020016947A (ko) 2002-03-06
HUP0202397A2 (en) 2002-10-28
CZ300513B6 (cs) 2009-06-03
NO20020605L (no) 2002-02-07
IL148057A (en) 2008-04-13
CN1370069A (zh) 2002-09-18
BG65366B1 (bg) 2008-04-30
MXPA02001373A (es) 2002-07-30
MY129668A (en) 2007-04-30
BG106391A (en) 2002-09-30
UA73137C2 (en) 2005-06-15
CA2378428A1 (en) 2001-02-15
SK285587B6 (sk) 2007-04-05
HUP0202397A3 (en) 2006-07-28
JP2003506403A (ja) 2003-02-18
DE50008527D1 (de) 2004-12-09
YU8302A (sh) 2004-12-31
DE19937304C2 (de) 2003-08-21
HRP20020117A2 (en) 2003-10-31
ATE281168T1 (de) 2004-11-15
NZ517367A (en) 2004-09-24
IL148057A0 (en) 2002-09-12
KR100713573B1 (ko) 2007-05-02
EE04928B1 (et) 2007-12-17
CZ2002497A3 (cs) 2002-06-12
WO2001010425A2 (de) 2001-02-15
CA2378428C (en) 2009-10-20
BR0013009A (pt) 2002-04-30
WO2001010425A3 (de) 2002-02-07
AU6992800A (en) 2001-03-05
EP1207884B1 (de) 2004-11-03
EA200200207A1 (ru) 2002-08-29
CN1166361C (zh) 2004-09-15
EA007531B1 (ru) 2006-10-27
SK1972002A3 (en) 2002-06-04
HK1046854B (zh) 2005-02-25
AR025078A1 (es) 2002-11-06
ES2231243T3 (es) 2005-05-16
EP1207884A2 (de) 2002-05-29
TWI285550B (en) 2007-08-21
ZA200200997B (en) 2002-10-30
TR200200359T2 (tr) 2002-05-21
PT1207884E (pt) 2004-12-31
EE200200061A (et) 2003-04-15
PL364049A1 (en) 2004-12-13
AU777709B2 (en) 2004-10-28
DE19937304A1 (de) 2001-03-15
HK1046854A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
NO20020605L (no) Anvendelse av CGRP-antagonister og CGRP- frigjoringsinhibitorer for bekjempelse av menopause-varmetokter
NO20023729D0 (no) Preparater med regulert frigivelse inneholdende opioidagonist og -antagonist
ATE253576T1 (de) 8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren
IL145882A0 (en) Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors
PL347884A1 (en) Substituted benzimidazoles and their use as parp inhibitors
CY2008010I1 (el) Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες
DE60132799D1 (de) Peroxisom proliferator aktivierten rezeptor alpha agonisten
NO20021329L (no) Kinaseinhibitorer som terapeutiske midler
EP1383743A4 (en) DOUBLE INHIBITORS OF PDE 7 AND PDE 4
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20012013D0 (no) 5HT1 reseptor agonister og metoclopramid for behandling av migrene
EE200400042A (et) 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena
HUP0401756A3 (en) Substituted benzimidazole compounds and their use
DK1131083T3 (da) Anvendelse af væksthormonfrigørende forbindelser og antagonister deraf til behandling af tumorer
IS2536B (is) Lyfjablanda úr PDE4 eða PDE3/4 tálma og histamínviðtakamótlyfi
PT1206462E (pt) Compostos heterociclicos para inibicao da angiogenese
HUP0500078A3 (en) Pharmaceutical composition containing a combination of a pde inhibitor and a leukotriene receptor antagonist
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
ID28227A (id) Penggunaan farmasi baru untuk inhibitor nos
HUP0001888A3 (en) Pharmaceutical composition containing 5ht1 receptor agonists and either cox-2 inhibitor or nsaid for the treatment of migraine
IL136961A0 (en) 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
NO20025282D0 (no) Peptid-deformylase-inhibitorer
NO20020291D0 (no) Preventive og terapeutiske midler for kreft
EE200300075A (et) Angiotensiin II antagonistide ja ACE inhibiitorite farmatseutiline kombinatsioon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application